Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer by Ribi, K et al.
 
Subjective cognitive complaints one year after ceasing adjuvant
endocrine treatment for early-stage breast cancer
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Ribi, K, J Aldridge, K-A Phillips, A Thompson, V Harvey, B
Thürlimann, F Cardoso, et al. 2012. Subjective cognitive
complaints one year after ceasing adjuvant endocrine treatment
for early-stage breast cancer. British Journal of Cancer 106(10):
1618-1625.
Published Version doi:10.1038/bjc.2012.156
Accessed February 19, 2015 12:08:21 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11178965
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAASubjective cognitive complaints one year after ceasing adjuvant
endocrine treatment for early-stage breast cancer
K Ribi
1, J Aldridge
2, K-A Phillips
3, A Thompson
4, V Harvey
5,6, B Thu ¨rlimann
7,8, F Cardoso
9,17, O Pagani
8,10,
AS Coates
1,11, A Goldhirsch
12,13, KN Price
2,14, RD Gelber
2,14,15, J Bernhard*,1,16 and for the BIG 1-98
Collaborative Group and the International Breast Cancer Study Group (IBCSG)
1IBCSG Coordinating Center, Effingerstr. 40, Bern 3008, Switzerland;
2Department of Biostatistics and Computational Biology, IBCSG Statistical Center,
Dana-Farber Cancer Institute, MA 02215, USA;
3Peter MacCallum Cancer Centre and The University of Melbourne, Locked Bag 1A’ Beckett Street,
Melbourne 8006, Victoria, Australia;
4Dundee Cancer Centre, University of Dundee, Dundee, UK;
5Auckland City Hospital, Private Bag, 92024,
Auckland1, New Zealand;
6Australian New Zealand Breast Cancer Trials Group, PO Box 155, HRMC NSW 2310, Australia;
7Breast Center,
Kantonsspital, Rorschacherstr. 95, 9007, St. Gallen, Switzerland;
8Swiss Group for Clinical Cancer Research (SAKK), Effingerstr. 40, Bern, 3008,
Switzerland;
9Department of Medical Oncology; Jules Bordet Institute, Brussels, Belgium;
10Oncology Institute of Southern Switzerland, Ospedale Italiano,
Viganello, Lugano, Switzerland;
11University of Sydney, School of Public Health, Sydney, Australia;
12Department of Medicine, European Institute of
Oncology, Via Ripamonti 435, Milan 20141, Italy;
13Swiss Center for Breast Health, Sant’Anna Clinics, Building C, Lugano-Sorengo 6924 Switzerland;
14Frontier Science and Technology Research Foundation, Boston, MA 02215, USA;
15Harvard School of Public Heath, Harvard Medical School,
Boston, MA 02215, USA;
16Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland
BACKGROUND: In the BIG 1-98 trial objective cognitive function improved in postmenopausal women 1 year after cessation of adjuvant
endocrine therapy for breast cancer. This report evaluates changes in subjective cognitive function (SCF).
METHODS: One hundred postmenopausal women, randomised to receive 5 years of adjuvant tamoxifen, letrozole, or a sequence of
the two, completed self-reported measures on SCF, psychological distress, fatigue, and quality of life during the fifth year of trial
treatment (year 5) and 1 year after treatment completion (year 6). Changes between years 5 and 6 were evaluated using the
Wilcoxon signed-rank test. Subjective cognitive function and its correlates were explored.
RESULTS: Subjective cognitive function and the other patient-reported outcomes did not change significantly after cessation of
endocrine therapy with the exception of improvement for hot flushes (P¼0.0005). No difference in changes was found between
women taking tamoxifen or letrozole. Subjective cognitive function was the only psychosocial outcome with a substantial correlation
between year 5 and 6 (Spearman’s R¼0.80). Correlations between SCF and the other patient-reported outcomes were generally low.
CONCLUSION: Improved objective cognitive function but not SCF occur following cessation of adjuvant endocrine therapy in the BIG
1-98 trial. The substantial correlation of SCF scores over time may represent a stable attribute.
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Cognitive deficits following adjuvant breast cancer therapy have
been increasingly investigated over the past decade. Earlier studies
focused mainly on chemotherapy (Vardy et al, 2007; Vardy, 2009),
but more recent research has examined the potential aetiological
role of adjuvant endocrine therapies (Jenkins et al, 2004; Bender
et al, 2007; Hermelink et al, 2008; Jenkins et al, 2008; Collins et al,
2009; Debess et al, 2010; Phillips et al, 2010; Schilder et al,
2010; Phillips et al, 2011a, b). In these previous studies, objective
cognitive function was usually measured with standardised
neuropsychological tests (Vardy, 2009; Phillips et al, 2011a, b). If
subjective cognitive complaints were assessed, a range of validated
self-report questionnaires, ‘self-developed’ non-validated ques-
tionnaires and/or semi-structured interviews were used (Pullens
et al, 2010). The prevalence of subjective cognitive dysfunction in
women with breast cancer ranged from 21 to 90%, and there was no
association between objective cognitive function and SCF (Pullens
et al, 2010). Most studies on cognitive function also included
measures of psychological distress (mainly depression and anxiety),
quality of life (QOL), and fatigue as potential covariates.
Irrespective of therapy received (i.e., chemotherapy or endo-
crine therapy or both), or of study design (cross-sectional vs
longitudinal), studies in women with breast cancer have consis-
tently reported that objective cognitive function is not related to
psychological distress (Jenkins et al, 2004; Shilling et al, 2005;
Bender et al, 2006; Hermelink et al, 2007), fatigue (Fan et al, 2005;
Bender et al, 2006; Jenkins et al, 2006; Mehnert et al, 2007; Collins
et al, 2009), or QOL (Fan et al, 2005; Shilling et al, 2005; Jenkins
et al, 2006; Mehnert et al, 2007). Only one study found that better
scores in cognitive function were weakly related to less fatigue
2 years after chemotherapy completion (Schilder et al, 2008).
In contrast, several studies found SCF to be associated with
psychological distress (Castellon et al, 2004; Jenkins et al, 2004;
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sHermelink et al, 2007; Jenkins et al, 2008; Weis et al, 2009). There
are few longitudinal studies that have investigated subjective
cognitive and psychosocial changes in women with breast cancer
during adjuvant endocrine therapy (Jenkins et al, 2006; Jenkins
et al, 2008; Collins et al, 2009; Legault et al, 2009), and none of
them specifically studied changes in these factors after ceasing
therapy. One study examined the relationship between cognitive
limitations and tamoxifen or aromatase inhibitors in employed
breast cancer survivors on average 3 years after primary treatment
(Breckenridge et al, 2012). Exposure to endocrine therapy was not
related to scores on the objective measures, but moderately related
to perceived attentional problems at work and perceived cognitive
functioning in everyday life.
We have previously reported results from the BIG 1-98 study
on objective cognitive function (Phillips et al, 2010; Phillips et al,
2011a, b). There was a statistically significant improvement in
objective cognitive function after cessation of adjuvant endocrine
therapy, with an effect size large enough to be considered clinically
meaningful (Phillips et al, 2011a, b). In this report, we present the
findings on SCF, psychological distress, fatigue, and QOL. Thus,
objectives of the study reported here were (1) to evaluate changes
in SCF, psychological distress, fatigue, and QOL 1 year after the
cessation of adjuvant endocrine therapy in postmenopausal
women with early breast cancer, who were randomised within a
double blind controlled trial (BIG1-98) (Thurlimann et al, 2005;
Mouridsen et al, 2009) to receive adjuvant tamoxifen or letrozole
alone or in sequence; (2) to evaluate whether there are differences
in changes in SCF and other psychosocial outcomes 1 year after the
cessation of adjuvant endocrine therapy between women taking
tamoxifen or letrozole for the last 3 of 5 years of trial treatment;
and (3) to evaluate the relationship between cognitive function
(objective and subjective), psychological distress, fatigue, and QOL
while still on treatment and 1 year after cessation. In addition,
subjective complaints of cognitive dysfunction and their correlates
were explored.
MATERIALS AND METHODS
The BIG 1-98 trial (March 1998–May 2003) randomised 8010
postmenopausal women with hormone receptor-positive tumours
to receive one of four adjuvant endocrine therapy options
after stratification by institution and chemotherapy (Figure 1).
A sub-study assessed cognitive function and psychosocial factors
at year 5 (during the fifth year on endocrine therapy (Phillips et al,
2010) and at year 6 (B1 year after ceasing therapy (Phillips et al,
2011a, b). The sub-study protocol was approved by the local and
International Breast Cancer Study Group (IBCSG) ethics commit-
tees and the required health authorities of each participating
centre. All women gave informed consent to participate in the sub-
study and parent study.
Cognitive function and patient-reported outcomes
Objective cognitive function was assessed using a brief compu-
terised test battery (CogState Ltd; http://www.cogstate.com), which
is free from practice effects (Collie et al, 2001; Falleti et al, 2003;
Snyder et al, 2005; Vardy et al, 2006). Testing consisted of five
non-verbal tasks, measuring the speed of psychomotor function,
visual attention, attention and working memory, and visual
learning and memory. In addition, two verbal learning and
memory tasks required subjects to learn a 12-word shopping list,
and then to recall this list after 20min. Details of the test battery
have been described elsewhere (Phillips et al, 2010). For the seven
tasks, a composite score, representing the age-adjusted average
standardised score of each task for each individual, was calculated
(Phillips et al, 2010).
After cognitive testing, women completed several question-
naires. Subjective cognitive function was assessed with the
Cognitive Failures Questionnaire (CFQ (Broadbent et al, 1982)),
a 25-item self-report measure that assesses a person’s failures in
memory, perception, attention, and motor function over the past 6
months. The response categories range from 0 (‘never’) to 4 (‘very
often’). Studies exploring potential CFQ subscales vary consider-
ably with regard to the number of subscales identified, so in this
study only the global summary score was used (Broadbent et al,
1982). To measure psychological distress, a 12-item version of the
General Health Questionnaire (GHQ-12 (Goldberg, 1992; Politi
et al,1 9 9 4 ;S c h m i t zet al, 1999; Donath, 2001) was used. In addition,
the Brief Fatigue Inventory (BFI (Mendoza et al, 1999), a 9-item
instrument to assess severity of fatigue and its inference with daily
living in a 24-h period, was administered. Various global and
symptom-specific QOL domains were measured by linear analogue
self-assessment indicators (Bernhard et al, 1997). Validated
language versions were used where available, otherwise a standard
translation procedure was performed (forward-backward).
Statistical considerations
Changes in SCF and each of the patient-reported outcome
measures from year 5 to year 6 were evaluated by subtracting
year 5 from year 6 scores. Higher scores reflect a poorer condition;
thus, a negative change in the score indicates an improvement.
Owing to the skewness in the distribution of responses for the BFI,
GHQ, and QOL measures at the year 5 assessment, analyses were
performed using nonparametric methods. The stratified Wilcoxon
signed-rank test was used to evaluate changes 1 year after cessation
of adjuvant endocrine therapy (regardless of the type of endocrine
therapy received). The Van Elteren Wilcoxon rank-sum test,
stratified on language, was used to test the difference in the
changes from year 5 to year 6 between women taking tamoxifen
and women taking letrozole at year 5. Spearman’s correlation
coefficients (R) were obtained for pairwise associations among the
CogState Battery composite score and the self-reported measures.
Where available, cut-offs were applied to identify women with
mental disorders or severe fatigue. A widely accepted convention
to define a case of mental disorder using the GHQ-12 is a score X3
(Goldberg et al, 1997). A score X31 is considered as cut-off for
screening of mental disorder for the QOL mood scale (Singer et al,
2008). A BFI score X8 represents severe fatigue (Chang et al,
2007). In the absence of an established cut-off for the CFQ total
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Figure 1 CONSORT diagram of the BIG 1-98 Cognitive Function
Substudy. T¼tamoxifen for 5 years; L¼letrozole for 5 years;
ET¼endocrine therapy; T-L¼tamoxifen for 2 years followed by
letrozole for 3 years; L-T¼letrozole for 2 years followed by tamoxifen
for 3 years; Y5¼cognitive function assessment taken at the end of 5 years
of ET; Y6¼cognitive function assessment taken B1 year after the
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sscore, we used a distribution-based measure and focused on
women who reported the highest 33% of CFQ total scores at year 5.
In order to characterise women who reported the highest 33%
of CFQ total scores at year 5 (still on treatment), relationships
between CFQ scores and their year-5 BFI, GHQ and mood scores,
age at this time, and year 6-CFQ scores were explored graphically
(scatter plots). These variables were chosen a priori because of
research showing strong associations between SCF and fatigue,
depression, anxiety and mood, and because of age being
considered an important covariate of cognitive function. Women
who reported the highest 33% of CFQ total scores at year 5 were
further characterised with regard to specific complaints (on CFQ
individual item level) by exploring the relationship between
individual complaints at year 5 and year 6.
RESULTS
Of 135 women recruited to this study, 35 were ineligible for this
analysis (see Figure 1 for reasons), leaving 100 women. The year-6
assessment was undertaken a median of 365.5 days (range 191–699
days) after ceasing protocol endocrine therapy.
Most patient and disease characteristics (i.e., age, history of
head injury, neurological disorder, anxiety or depression, currently
treated for anxiety, depression or mental disorder, alcohol
consumption, ECOG status, chemotherapy received, hormone
replacement therapy, ER/PgR status, tumour size, and local
therapy) were balanced between women who had both assessments
vs those who had only year-5 assessment (drop-outs N¼23; see
Figure 1), except that women who had four or more positive nodes
were more likely to drop out by the year-6 assessment (P¼0.01).
No statistically significant differences were found for patient and
disease characteristics between the women taking tamoxifen vs
letrozole at year 5.
Differences between treatments groups at year 5
At year 5, no differences were found for SCF (P¼0.79), fatigue
(P¼0.58), psychological distress (P¼0.16), or the QOL indicators
between women taking tamoxifen or letrozole.
Changes from on- to off-treatment
Overall, no significant change was found from on-treatment to
1-year off-treatment for SCF or any of the patient-reported
outcomes (Table 1), except for a significant decrease in hot flushes
(mean change (s.d.)¼ 10.3 (30.87); median change (range)¼
 2( 99, 100), P¼0.0005). Likewise, none of the changes in SCF
and other patient-reported outcomes differed significantly between
women taking tamoxifen compared with letrozole (data not
shown).
Prevalence of severe fatigue and psychiatric or mental
disorder
Regarding fatigue, no woman had a BFI score considered as
representing severe fatigue at year 5 and only one experienced
severe fatigue at year 6. About the same proportion of women had
GHQ scores defined as a case of mental disorder at year 5 (14%)
and year 6 (18%). Of those, 12 women changed from ‘no case’ at
year 5 to ‘case’ at year 6; however, 8 women improved, changing
from ‘case’ to ‘no case’. The proportion of women with mood
scores indicative for a mental disorder remained stable with 20%
of women at year 5 and 18% at year 6. Of those, 9 women
worsened, changing from not impaired at year 5 to impaired at
year 6; 11 women improved, going from impaired to not impaired.
Relationship between cognitive function and
patient-reported outcomes
There were no notable correlations between objective cognitive
function (composite score) and the various patient-reported
outcomes at year 5 or 6 (correlation coefficients ranged from
R¼ 0.15 to R¼0.18). In addition, no notable correlations were
found between individual Cogstate tasks and SCF, with correlation
coefficients ranging from R¼ 0.09 to R¼0.14 at year 5 and from
R¼ 0.02 to R¼0.19 at year 6. Subjective cognitive function
showed a low correlation with fatigue (BFI, R¼0.33), psycholo-
gical distress (GHQ, R¼0.31), mood (R¼0.45), tiredness
(R¼0.41), and physical well-being (R¼0.37) and no correlations
with the other QOL indicators at year 5. Similarly, at year 6
correlations between SCF and fatigue (BFI, R¼0.37), psychological
distress (GHQ, R¼0.42), and tiredness (R¼0.41) were low, and no
correlations with the other QOL indicators were found.
Subjective cognitive complaints and their correlates
For women with CFQ scores in the highest third, the lowest score
was 40 at the year-5 assessment. Thirty-eight women (38%) at year
5 and 36 women (36%) at year 6 had a CFQ score of X40.
Figure 2A–D shows plots of CFQ scores by GHQ, BFI, mood
scores, and age at year 5 for all patients. Whereas there seems to be
Table 1 Descriptive statistics of patient-reported outcomes by time point and change in score
Year 5(during the fifth year on ET) Year 6 (B1 year after ceasing ET) Change (year 6–year 5)
N Med Min Max N Med Min Max Mean Med s.d. Min Max P
a
CFQ 99 35.00 7.00 64.00 100 35.0 3.00 65.00  1.10  1.00 7.33  27.00 14.00 0.25
BFI 98 1.61 0.00 7.44 98 2.11 0.00 8.44 0.17 0.28 1.77  6.78 4.44 0.12
GHQ 100 0.00 0.00 10.00 99 0.00 0.00 10.00 0.13 0.00 2.38  10.00 10.00 0.28
QOL indicators
Physical well-being 100 9.5 0 94 98 13.0 0 100 1.09 0.5 22.64  79 99 0.45
Mood 100 8.0 0 97 98 12.0 0 100 1.45 0.0 20.69  61 94 0.56
Tiredness 100 22.0 0 96 98 30.0 0 100 4.05 4.5 28.49  80 76 0.09
Appetite 100 5.5 0 84 98 6.5 0 100 0.16 0.0 22.65  72 99 0.70
Hot flushes 100 20.0 0 100 98 6.0 0 100  10.3  2.0 30.87  99 100 0.0005
Feeling sick 100 2.0 0 77 98 1.0 0 100  0.66 0.0 18.18  76 100 0.32
Effort to cope 100 6.0 0 88 99 4.0 0 100  2.44  1.0 20.59  88 100 0.12
Arm restriction 100 3.0 0 95 99 4.0 0 100 1.73 0.0 23.26  76 100 0.38
Subjective health 100 10.0 0 86 98 11.0 0 100 0.14 0.0 20.53  85 100 0.85
Abbreviations: ET¼endocrine therapy; Med¼median; Min¼minimum; Max¼maximum; CFQ¼Cognitive Failure Questionnaire; BFI¼Brief Fatigue Inventory;
GHQ¼General Health Questionnaire. For all outcomes, higher scores reflect a poorer condition, and a negative change indicates an improvement.
aP-value calculated
using the Wilcoxon signed-rank test.
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ssome tendency for women who reported the highest 33% of SCF
scores (vertical line represents the cut-off) to have worse BFI and
mood scores, this is not seen with the GHQ score or age. Women
with more cognitive complaints at year 5 (i.e., still on treatment)
also reported more complaints at year 6 (i.e., after ceasing
endocrine treatment; R¼0.80), as shown in Figure 3. In contrast,
correlations between on- and off-treatment scores were lower for
BFI (R¼0.53), GHQ (R¼0.39) or the various QOL indicators
(ranging from R¼0.32 to 0.62).
There were moderate-to-high correlations between responses at
year 5 and those at year 6 for individual CFQ items (ranging from
R¼0.24 to 0.77). When the individual complaints of women with
the highest 33% of CFQ total scores at year 5 were explored
(Figure 4), four items pertaining to memory lapses (i.e., ‘forgetting
reason for going from one part of house to the other’, ‘forget where
you put things’, ‘forget people’s names’, ‘cannot remember
something (on tip of tongue)’), had high responses for both years
5 and 6, suggesting that these were the most bothersome specific
complaints in this particular subgroup of women, and that they
remained a problem during treatment (year 5) and 1 year after
treatment cessation (year 6).
In summary, although objective cognitive function improved 1
year after treatment completion in the BIG 1-98 Trial (Phillips
et al, 2011a, b), hot flushes reduced, and SCF and the other
psychosocial measures remained stable with no difference between
women taking tamoxifen and letrozole.
DISCUSSION
In this sub-study, SCF, fatigue, psychological distress, and QOL did
not change between the fifth year on adjuvant endocrine therapy
and 1 year after treatment cessation in postmenopausal women
with early-stage breast cancer. The only exception was a significant
decrease in hot flushes, which is expected on withdrawal of
endocrine therapy. Similarly, the proportion of women who were
at risk for a mental disorder was stable, with rates o20% at year 5
and 6. Other studies on cognitive function in women with breast
cancer using also the GHQ-12 to control for mental disorder have
reported similar rates of risks for mental disorder in women
receiving radiotherapy and/or endocrine therapy (Jenkins et al,
2006), but higher rates in women receiving chemotherapy (Shilling
et al, 2005).
To our knowledge, this is the first study reporting on subjective
cognitive changes in women after cessation of endocrine therapy
for early-stage breast cancer within a randomised controlled trial
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Figure 2 Plots of SCF on psychological distress (GHQ, A), fatigue (BFI, B), mood (C) and age (D) at year 5. The vertical line represents the cut-off
for women who reported the highest 33% of SCF (CFQ) scores.
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ssetting. Most studies reporting on changes in SCF have focused on
subjective cognitive changes after chemotherapy (Hurria et al,
2006; Jenkins et al, 2006; Shilling and Jenkins, 2007; Jansen et al,
2008; Quesnel et al, 2009). In the study by Jenkins (Jenkins et al,
2006), one group of patients received radiotherapy and/or
endocrine therapy only. In this group no subjective cognitive
changes were found over time, but patients were still taking
endocrine treatment at the time of their follow-up assessment. In a
randomised double-blind chemoprevention trial (IBIS II trial
(Jenkins et al, 2008), postmenopausal women at high risk for
breast cancer did not report changes in SCF (assessed with the
CFQ) during the first two years on the aromatase inhibitor
anastrozole.
The fact that in our study SCF remained stable suggests that it
may represent a stable attribute. The argument, made by some
authors, that subjective cognitive complaints in women treated for
breast cancer may solely represent psychological distress or fatigue
(Morse et al, 2003; Pullens et al, 2010) is undermined by our
finding of only weak-to-moderate associations among SCF and
these measures. Similarly, the correlation between on- and
off-treatment scores was low for psychosocial distress, moderate
for fatigue but substantial for SCF. An alternative hypothesis is
therefore that self-report instruments purporting to measure
cognitive function, may in fact be measuring a stable, psycholo-
gical factor. In one study of patients receiving chemotherapy for
breast cancer, the personality trait ‘negative affectivity’ was one of
the determinants of cognitive self-reports (Hermelink et al, 2010).
Our exploratory analysis showed that among women in the
highest third of SCF scores at the end of treatment, there were few
specific cognitive problems persisting over time, in particular four
specific lapses concerning memory. Shilling and Jenkins (2007)
interviewed women with breast cancer receiving adjuvant therapy,
who reported memory problems regarding the kind of problems
they encountered. Few were able to mention more than one to two
specific cognitive problems. A notable problem was remembering
what they are doing, or were supposed to have done that is similar
to the problem of ‘forgetting reason for going from one part of
house to the other’ in our study. Other frequently reported
problems (e.g., forgetting the names of people, forgetting
appointments, forgetting where things are, and remembering a
word they wished to use) were also consistent with the kind of
problems reported as most bothersome by the women who
reported the highest 33% of SCF scores. There was no indication
that these women differed substantially from the rest of the sample
with respect to age, psychological distress or fatigue. This is in
contrast to studies reporting evidence for a moderate-to-strong
relationship between SCF and psychological distress, fatigue or
QOL during and after adjuvant treatment for breast cancer
(Jenkins et al, 2006; Shilling and Jenkins, 2007; Weis et al, 2009;
Breckenridge et al, 2012).
In line with the existing evidence, we found no association
between objective cognitive function and SCF. It has been argued
that the reason for this dissociation may be that standardised
neuropsychological tests are insufficiently sensitive to detect mild
impairments in cancer patients (Schagen et al, 2009). Furthermore,
objective cognitive tests are usually conducted at specific time
points in a clearly defined test situation, and therefore may fail to
assess cognitive function in relevant everyday settings (Sbordone,
2001) or to cover a broader time period (Tannock et al, 2004).
There are some limitations to consider. In the absence of an
established cut-off or normative data for the CFQ, we had to rely
on an arbitrary, distribution-based criterion. This frame of
reference allowed an exploration of the clinical observation, that
there is a subgroup of patients with complaints of cognitive
impairment persisting after completing adjuvant therapy. The lack
of a definition for subjective cognitive impairment is a general
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sproblem; only 7 out of 27 studies conducted in women with breast
cancer (Pullens et al, 2010) described the definition of subjective
cognitive dysfunction, using either theoretical definitions or cut-
offs. At the time the study was designed, subjective data from
women with breast cancer indicated that they were concerned
most about their ability to concentrate and remember, and none of
the available studies had highlighted executive function as an area
of specific concern. In a recent review, subjective cognitive deficits
consisted of problems with memory, concentration, language, and
self-reported retardation in mental processes or lower effectiveness
(Pullens et al, 2010). Yet, it is possible that our study missed
patients with executive function deficits, which may be correlated
with changes in SCF. We had no assessment of cognitive function
before the start of endocrine therapy and were not able to control
for the potential preexistence of cognitive impairment.
In conclusion, it is reassuring that objective cognitive function
improves significantly after ceasing endocrine therapy (Phillips et al,
2011a, b). However, given the results reported here, there is a
subgroup of women who may not feel that their everyday cognitive
abilities, in particular those related to memory, are better after ceasing
therapy. The quite clear disconnect between objective cognitive
function and SCF, whatever the underlying reason, is a crucial issue
that must be addressed in subsequent research, in order for the
research community to respond effectively to the concerns of women
about their cognition during and after breast cancer treatment.
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